Received 16 July 2003 Accepted 25 July 2003

Online 31 July 2003

6433.

CDRI communication No.

Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

Ashoke Sharon,^a Tumul Srivastava,^b B. S. Katti^b and Prakas R. Maulik^a*

^aMolecular and Structural Biology Division, Central Drug Research Institute, Lucknow 226 001, India, and ^bMedicinal Chemistry Division, Central Drug Research Institute, Lucknow 226 001, India

Correspondence e-mail: maulik_prakas@yahoo.com

Key indicators

Single-crystal X-ray study T = 293 KMean $\sigma(C-C) = 0.004 \text{ Å}$ R factor = 0.048 wR factor = 0.119 Data-to-parameter ratio = 16.7

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

2-(4-Chlorophenyl)-3-cyclohexylthiazolidin-4-one

The thiazolidine ring of the title molecule, $C_{15}H_{18}$ ClNOS, is planar within 0.042 (3) Å and the cyclohexane ring adopts a chair conformation. The molecular structure is stabilized by weak $C-H\cdots O$ and $C-H\cdots \pi$ interactions. In the crystal structure, bifurcated $C-H\cdots O$ interactions link symmetryrelated molecules to form dimers.

Comment

The therapeutic importance of suitably functionalized thiazolidinone ring systems (Anders et al., 2001; Tanabe et al., 1995; Diurno et al., 1992) has encouraged us to develop an innovative synthesis in which different substituents could be arranged in a pharmacophoric pattern to display diverse pharmacological activities of higher order (Srivastava et al., 2002). Since not much is known about the exact binding site of this class of molecules we thought it appropriate to generate X-ray crystal data of a prototype. Hence the X-ray structure determination of the title compound was undertaken. The data generated, especially 'non-covalent interactions' could be used for structural study and correlation. Non-covalent interactions play a significant role in molecular recognition, stabilization of DNA/RNA structures (Hobza & Sponer, 1999), crystal engineering (Desiraju, 1995) and drug development (Meyer et al., 2003).



In the title molecule, (I) (Fig. 1), the central thiazolidinone ring is planar within 0.042 (3) Å and its conformation may be described as flattened envelope, with S1 deviating from the C2/N3/C4/C5 plane by 0.139 (1) Å. The cyclohexane ring adopts a chair conformation. The dihedral angle between the C2/N3/C4/C5 plane and the chlorophenyl ring is 83.5 (1)°. The molecular structure is stabilized by $C-H\cdots O$ and $C-H\cdots \pi$ interactions (Fig. 1 and Table 1). The crystal packing reveals that a molecule and its inversion equivalent are linked by bifurcated $C-H\cdots O$ interactions to form dimers (Fig. 2). The crystal structure is further stabilized by van der Waals interactions.

Experimental

© 2003 International Union of Crystallography Printed in Great Britain – all rights reserved The title compound was prepared from *p*-chlorobenzaldehyde and mercapotacetic acid, according to a literature procedure (Srivastava





Displacement ellipsoid plot (30% probability), showing the molecular structure and the atom-labelling for the title compound. Non-covalent interactions are shown as dashed lines.

et al., 2002) and diffraction quality crystals were obtained by slow evaporation from a mixture of ethyl acetate and hexane (1:1).

 $D_{\rm r} = 1.348 {\rm Mg} {\rm m}^{-3}$

Cell parameters from 40

Mo $K\alpha$ radiation

reflections

 $\theta = 5.1 - 12.5^{\circ}$ $\mu = 0.40 \text{ mm}^{-1}$

T = 293 (2) K

 $h = -1 \rightarrow 21$

 $k = -1 \rightarrow 12$

 $l = -21 \rightarrow 20$

Block, colourless

 $0.25 \times 0.20 \times 0.18 \text{ mm}$

3 standard reflections

every 97 reflections

intensity decay: none

 $w = 1/[\sigma^2(F_o^2) + (0.0439P)^2$

where $P = (F_o^2 + 2F_c^2)/3$

+ 1.3546P]

 $\Delta \rho_{\rm max} = 0.21 \text{ e} \text{ Å}^{-3}$

 $\Delta \rho_{\rm min} = -0.21 \text{ e} \text{ Å}^{-3}$

 $(\Delta/\sigma)_{\rm max} < 0.001$

frequency: 60 min

Crystal data

 $\begin{array}{l} C_{15}H_{18}\text{CINOS} \\ M_r = 295.81 \\ \text{Monoclinic, } C2/c \\ a = 17.600 \ (1) \ \text{\AA} \\ b = 9.775 \ (1) \ \text{\AA} \\ c = 17.089 \ (1) \ \text{\AA} \\ \beta = 97.33 \ (1)^{\circ} \\ V = 2916.0 \ (4) \ \text{\AA}^3 \\ Z = 8 \end{array}$

Data collection

Bruker P4 diffractometer θ -2 θ scans Absorption correction: none 3556 measured reflections 2866 independent reflections 1731 reflections with $I > 2\sigma(I)$ $R_{int} = 0.023$ $\theta_{max} = 26.0^{\circ}$

Refinement

Refinement on F^2 $R[F^2 > 2\sigma(F^2)] = 0.048$ $wR(F^2) = 0.119$ S = 1.022866 reflections 172 parameters H-atom parameters constrained

Table 1

Hydrogen-bonding geometry (Å, $^\circ)\!.$.

$D - H \cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdots A$	$D - H \cdot \cdot \cdot A$
$C5-H5B\cdotsO18^{i}$	0.97	2.56	3.226 (4)	126
$C7-H7\cdots O18^{i}$	0.93	2.68	3.601 (3)	169
C12-H12···O18	0.98	2.31	2.785 (3)	109
$C13-H13A\cdots Cg1$	0.97	2.99	3.717 (3)	133

Symmetry codes: (i) $\frac{1}{2} - x$, $\frac{1}{2} - y$, -z. Cg1 denotes the centroid of the substituted phenyl ring.



Figure 2

A view of the bifurcated C-H···O interactions leading to the formation of a dimer. Atoms labelled with the suffix A are at the symmetry position $(\frac{1}{2} - x, \frac{1}{2} - y, -z)$, *i.e.* symmetry code (i) in Table 1.

All H atoms were placed in calculated positions and allowed to ride on their parent C atoms, with C—H = 0.93–0.98 Å and $U_{\rm iso}({\rm H})$ = $1.2U_{\rm eq}({\rm C})$.

Data collection: *XSCANS* (Siemens, 1996); cell refinement: *XSCANS*; data reduction: *XSCANS*; program(s) used to solve structure: *SHELXTL* (Bruker, 1997); program(s) used to refine structure: *SHELXTL*; molecular graphics: *SHELXTL*; software used to prepare material for publication: *SHELXTL*.

AS and TS thank CSIR, India, for providing Senior Research Fellowship.

References

- Anders, C. J., Bronson, J. J., D'Andrea, S. V., Deshpande, S. M., Falk, P. J., Grant-Young, K. A., Harte, W. E., Ho, H., Misco, P. F., Robertson, J. G., Stock, D., Sun, Y. & Walsh, A. W. (2001). *Bioorg. Med. Chem. Lett.* pp. 715– 717.
- Bruker (1997). SHELXTL. Version 5.10. Bruker AXS Inc., Madison, Wisconsin, USA.
- Desiraju, G. R. (1995). Angew. Chem. Int. Ed. Engl. 34, 2311-2327.
- Diurno, M. V., Mazzoni, O., Calignano, P. E., Giordano, F. & Bolognese, A. J. (1992). J. Med. Chem. 35, 2910–2912.
- Hobza, P. & Sponer, J. (1999). Chem. Rev. 99, 3247-3276.
- Meyer, E. A., Castellano, R. K. & Diederich, F. (2003). Angew. Chem. Int. Ed. Engl. 42, 1210–1250.
- Siemens (1996). XSCANS. Version 2.21. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
- Srivastava, T., Haq, W. & Katti, S. B. (2002). Tetrahedron, 58, 7619–7624.
- Tanabe, Y., Yamamoto, H., Murakami, M., Yanagi, K., Kubota, Y., Okumura, H., Sanemitsu, Y. & Suzukamo, G. J. (1995). J. Chem. Soc. Perkin Trans. 1, pp. 935–947.